In this podcast, Drs. Linda Martin and Jessica Donington discuss the evolving approach to treating N2 disease in stage 3 lung cancer, emphasizing the shift from therapeutic nihilism to more aggressive surgical strategies. They highlight the success of combining chemotherapy, immunotherapy, and surgery, which has led to improved outcomes, especially in patients with multi-station N2 disease, while noting the importance of rethinking traditional treatment paradigms and focusing on systemic control rather than local clearance alone.